25 matches for your search in the start-up spotlight
rss
Cambridge-based TRIMTECH Therapeutic’s mission is to create novel small molecule degraders of protein aggregates that will combat neurodegenerative and inflammatory diseases including Alzheimer’s disease, a leading cause of death globally. The Company’s proprietary degrader technology is focused ...
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for ...
PharmaKure, a clinical stage pharmaceutical company is targeting neurodegenerative diseases including Alzheimer’s and Parkinson’s Diseases and other rare diseases. The company’s propriety technology allows the diagnosis and monitoring of drug treatment for patients using blood-based ...
DIOSynVax customises vaccine antigen design to maximise the protection that vaccines can provide worldwide against existing and future viruses. Grounded firmly in virus structure and evolution, our method is patent protected, combining computational biology with in vitro and in vivo validation, ...
NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours. Our technologies are built on pioneering research carried out by Hugh Brady and ...
Established in 2018, Ikarovec is developing novel, differentiated gene therapies for major ophthalmic indications. Its lead product, a bicistronic gene therapy for geographic atrophy, is in preclinical studies, and earlier programmes are targeting wet-form age-related macular degeneration (AMD), ...
Imophoron was founded in 2017 and is based at Science Creates in Bristol, UK. Imophoron has developed a novel next-generation nanoparticle platform, ADDomer™, initially focused on the development of vaccines to combat present and future infectious diseases, including ‘Disease X’ outbreaks. ...
Grey Wolf is a UK and Australian-based drug discovery and development company focused on developing novel immuno-oncology agents. The company was founded in 2017 by experienced industry professionals; Tom McCarthy (Executive Chairman; former President and CEO of Spinifex Pharmaceuticals), and ...
NRG Therapeutics is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND). The ...
Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon's lead program is a ...
